|
World | Condition | Intervention | Time frame | Phase/Status |
|
Florida (USA) | Chronic ischemic LV dysfunction secondary to MI | 10 and 20 intramyocardial injections of 2 million MSCs (low dose) or 20 million (high dose)/0.25–0.5 cm3 for a total of 20 million or 200 million cells, respectively | 6–18 months | Phase I/II (unknown) |
Chronic ischemic LV dysfunction and heart failure secondary to MI | Transendocardial injection of autologous human cells (bone marrow or mesenchymal). 40 million cells/mL delivered in either a dose of 0.25 mL/injection for a total of 100 million × 10 injections or a dose of 0.5 mL/injection for a total of 200 million × 10 injections | 6–18 months | Phase I/II (unknown) |
Chronic ischemic LV dysfunction secondary to MI | Transendocardial injection of autologous versus allogeneic MSCs. 40 million cells/mL delivered in either a dose of 0.5 mL/injection × 1 injection for a total of 20 million, a dose of 0.5 mL/injection × 5 injections for a total of 100 million, or a dose of 0.5 mL/injection × 10 injections for a total of 200 million MSCs | 6–13 months | Phase I/II (active) |
Nonischemic dilated cardiomyopathy | Transendocardial injection of autologous versus allogeneic MSCs. 20 million cells/mL delivered in a dose of 0.5 mL/injection × 10 injections for a total of 100 million of MSCs | 6–12 months | Phase I/II (active) |
|
Maryland (USA) | Chronic ischemic LV dysfunction secondary to MI | 10 and 20 intramyocardial injections of 2 million MSCs (low dose) or 20 million (high dose)/0.25–0.5 cm3 for a total of 20 million or 200 million of autologous human MSCs, respectively | 6–18 months | Phase I/II (unknown) |
Chronic ischemic LV dysfunction secondary to MI | Transendocardial injection of autologous versus allogeneic MSCs. 40 million cells/mL delivered in either a dose of 0.5 mL/injection × 1 injection for a total of 20 million, a dose of 0.5 mL/injection × 5 injections for a total of 100 million, or a dose of 0.5 mL/injection × 10 injections for a total of 200 million MSCs | 6–13 months | Phase I/II (active) |
|
France (Europe) | Chronic myocardial ischemia; LV dysfunction | Transendocardial intramyocardial injections of 60 million autologous MSCs | 30 days–2 years | Phase I/II (active) |
|
China (East Asia) | ST-elevation MI | Intracoronary human umbilical WJ-MSC transfer | 4 months–1 year | Phase II (active) |
|
Korea (East Asia) | Acute MI | Intracoronary injection of single dose of autologous bone-marrow-derived MSCs (I million) cells/kg | 6 months | Phase II (completed) |
|
India (South Asia) | ST-elevation acute MI | A Single Dose of Intravenous infusion of Allogenic MSCs | 6 months | Phase I/II (active) |
|